Phase i/II trial of a therapeutic DNA vaccine for chronic hepatitis c virus (HCV) infection
Ended Awarded Last action
- Contract number
- HHSN26100006
- Awardee
-
Mayo Clinic UEI Y2K4F9RPRRG7
- Awarding agency
-
National Cancer Institute
National Institutes of Health, Department of Health and Human Services
- Obligated
- $725,839
Award facts
- Opportunity
-
- N01CN0501469 Solicitation number
- Contract value 100% obligated
- $725,839.16 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 541712 Research and Development in the Physical, Engineering, and Life Sciences (except Biotechnology)
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Cost No Fee
- Place of performance
- Rochester, MN 55905, USA
Award details come from SAM.gov/FPDS.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Funding Only Action | $5,662 | |
| Exercise an Option | $84,697 | |
| Exercise an Option | $84,697 | |
| Exercise an Option | $85,865 | |
| Exercise an Option | $86,842 | |
| Other Administrative Action | -$20,331 | |
| Other Administrative Action | -$8,853 | |
| Other Administrative Action | $0 | |
| Original award | $407,260 |
About this award
This is a $725,839.16 federal contract awarded by the National Cancer Institute (NCI) to Mayo Clinic, a large non-profit academic medical center, to conduct a Phase I/II clinical trial of a therapeutic DNA vaccine for chronic Hepatitis C Virus (HCV) infection. The contract is part of NCI's Cancer Prevention Agent Development Program focused on early phase clinical research.
Mayo Clinic has subcontracted portions of the trial work to Temple University and Drexel University, both located in Philadelphia, Pennsylvania. This contract does not have a set-aside designation, reflecting Mayo Clinic's status as a large institution. The NCI has also awarded Mayo Clinic a separate $9.9 million Indefinite Delivery/Indefinite Quantity (IDIQ) contract to support preclinical pharmacokinetic and pharmacology evaluations for the Experimental Therapeutics program, allowing the agency to efficiently access Mayo Clinic's cancer research expertise over multiple years.
Quick answers
Who was awarded contract HHSN26100006?
HHSN26100006 was awarded to Mayo Clinic by National Cancer Institute (National Institutes of Health) on September 9, 2014.
How much is contract HHSN26100006 worth?
The government has obligated $725,839 on HHSN26100006.
Is contract HHSN26100006 an order under another contract?
Yes. HHSN26100006 is a delivery order under HHSN261201200042I, an indefinite delivery contract.
Was contract HHSN26100006 competed?
The extent of competition for HHSN26100006 was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award